Consolidated Cash Flow Statements (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Cash flows from operating activities:
Net income (loss)	$ 114,345	$ 108,459	$ (24,901)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	50,174	55,279	55,857
Share-based compensation	11,241	12,177	11,748
Pension funding less than (greater than) pension expense	3,812	(4,289)	(8,973)
Asset impairment	2,549	16,574	27,751
Deferred income tax expense (benefit)	2,294	(11,577)	(23,421)
Provision for inventory obsolescence	1,160	3,210	4,550
Non-cash loss on derivatives and hedging instruments	0	2,893
Loss (gain) on sale of businesses and tangible assets		(44,847)
Loss (gain) on sale of businesses and tangible assets			17,184
Tax deficiency (benefit) related to share-based compensation	(1,790)	110	1,564
Income from equity method investment	(13,169)	(11,940)	(6,405)
Changes in operating assets and liabilities, net of the effects of currency exchange rate changes and acquired businesses:
Receivables	4,680	(39,458)	52,369
Inventories	(22,873)	(14,031)	50,645
Accounts payable	9,281	38,513	9,728
Accrued liabilities	12,317	(8,203)	(30,919)
Accrued taxes	(55)	(3,793)	7,597
Other assets	12,219	27,209	10,629
Other liabilities	(1,622)	(14,737)	(3,193)
Net cash provided by operating activities	184,563	111,549	151,810
Cash flows from investing activities:
Cash used to acquire businesses, net of cash acquired	(60,519)	(119,110)	(20,703)
Capital expenditures	(40,053)	(28,194)	(40,377)
Proceeds from disposal of businesses and tangible assets	1,213	138,952	2,031
Net cash used for investing activities	(99,359)	(8,352)	(59,049)
Cash flows from financing activities:
Payments under share repurchase program	(50,000)
Cash dividends paid	(9,410)	(9,412)	(9,373)
Debt issuance costs	(3,296)		(11,810)
Payments under borrowing arrangements		(46,268)	(193,732)
Borrowings under credit arrangements			193,732
Cash received upon termination of derivative instruments		4,217
Tax benefit (deficiency) related to share-based compensation	1,790	(110)	(1,564)
Proceeds from exercise of stock options	4,599	3,158	699
Net cash used for financing activities	(56,317)	(48,415)	(22,048)
Effect of currency exchange rate changes on cash and cash equivalents	(4,824)	(5,008)	10,753
Increase in cash and cash equivalents	24,063	49,774	81,466
Cash and cash equivalents, beginning of period	358,653	308,879	227,413
Cash and cash equivalents, end of period	$ 382,716	$ 358,653	$ 308,879